USSTOCK.TODAY
Weekend. Closed
Log in Sign up

Citi raises CRISPR Therapeutics price target on rising Casgevy demand

The Motley Fool +1 ·

CRSP
CRSP CRISPR Therapeutics AG
$53.39 +5.85%
View chart & analysis →
  1. 1Citi analyst Igal Noachovitz raised the price target range for CRSPR to $82-$88 due to increasing Casgevy demand.
  2. 2CRISPR Therapeutics recorded total revenue of $76 million in the second quarter.
  3. 3CRISPR Therapeutics expects to release a Phase 1 clinical update for CTX310 before the end of this year.

So what's the key point?

Experts expect CRISPR Therapeutics' stock price to rise as demand for Casgevy increases. The company generated $76 million in revenue during the second quarter of this year.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Fuel prices rise due to refining capacity shortages, boosting refinery profits Nasdaq +1 · yesterdayEU considers restrictions on imports of Chinese hybrid vehicles Moby +2 · yesterdayGorilla Technology Group Inc. submits letter of intent for first US data center acquisition Newsfile Corp. +2 · yesterday
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news